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Abstract The incidence of malignant melanoma has been
rising steadily for the last 30 years. Through physician and
patient education, surveillance of high-risk individuals, and
biopsy of any suspicious lesions, more lesions are being
diagnosed earlier, where there is a high cure rate.
Unfortunately many patients will still present with thicker
lesions or nodal involvement, which carries a significantly
worse prognosis. Over the past decade, there have been
several changes in the management of primary cutaneous
melanoma. These have stemmed from novel surgical
approaches, a new understanding of melanoma biology,
and randomized clinical trials designed to improve out-
come and decrease the morbidity of therapy. This article
will review the clinical evidence behind the current treat-
ment recommendations for primary cutaneous melanoma
as well as some of the emerging data on innovative
immunologic-approaches to melanoma treatment.
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Introduction
Melanoma is an increasingly prevalent disease, affecting
tens of thousands of people of all ages. In 2004, it is esti-
mated that there will be 55,100 new cases of melanoma
and 7,910 deaths due to melanoma in the United States
[1]. This will make melanoma the fifth most-common can-
cer in males and the seventh most-common cancer in
females. Routine surveillance of high-risk individuals and
biopsy of any suspicious lesion is critical for diagnosing
melanoma at an early stage, as patients presenting with
thicker lesions or regional nodal metastases have a signif-
icantly poorer prognosis. Once melanoma has spread to
the lymph nodes, the survival drops off precipitously.
Only 49% of all patients with nodal metastases survive 5
years (37% at 10 years), although the range is large: from
13% at 5 years for patients with the highest combination
of risk factors (ulceration, high regional lymph node bur-
den) to 69% at 5 years for the lowest combination of pre-
dictive factors [2]. This paper looks at the currently avail-
able treatment options for patients with primary cutaneous
melanoma.
Treatment of the primary lesion
William Norris first described the concept of wide local
excision of primary melanoma in 1857, and this remains
the mainstay of therapy for localized melanoma nearly
150 years later [3]. The excision of the primary tumor
with an adequate margin of normal-appearing skin down
to the underlying fascia is curative for localized cutaneous
melanoma. Limited excisions, such as excisional biopsies,
are associated with local recurrence rates in the range of
30%–60% [4]. In 1907, Handley recommended a 2.5-cm
margin after microscopic examination of strips of cuta-
neous melanoma and surrounding tissue from autopsy [5].
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The recommended surgical margin was later increased to
5 cm to prevent local recurrence and to include possible
microsatellites immediately adjacent to the excision site
[6, 7]. As the incidence of melanoma increased, there was
an emergence of interest in clinical trials to provide sci-
entific data to support these recommendations. 
Three prospective randomized studies compared these
wide excisions (4- or 5-cm margins) with a more conser-
vative 2-cm margin of resection. A multi-institutional
prospective randomized trial from France compared a 5-cm
margin with a 2-cm margin in 319 patients with
melanomas ≤2 mm thick.  There was no difference in
local recurrence rate or survival [8]. The Intergroup
Melanoma Committee conducted a randomized prospec-
tive study evaluating 2-cm versus 4-cm margins in 468
patients with intermediate thickness melanomas (1–4
mm) [9]. Again, there was no statistically significant dif-
ference in the local recurrence rate. Of note, there was a
statistically significant difference in the need for skin
grafts, with 46% of the 4-cm group requiring skin grafts
and only 11% of the 2-cm group. More recently, the
Intergroup Melanoma Surgical Trial has published their
long-term 10-year follow-up results. The 10-year survival
rates were not significantly different when comparing 2-cm
versus 4-cm margins of excision [10]. Finally, the
Swedish Melanoma Study Group compared 2-cm versus
5-cm margins of excision in 989 patients with melanomas
between 0.8 and 2 mm thick. There were local recurrences
in 1% of patients, equally distributed between the two
groups, and there were no differences in recurrence-free
or overall survival between the two study arms [11].
These data strongly demonstrate that a 2-cm margin for
intermediate-thickness melanomas (1–4 mm) is not only
safe and sufficient, but also significantly decreases the
need for the extra expense and morbidity associated with
a skin graft.
What about margins less than 2 cm? The World Health
Organization (WHO) Melanoma Group prospectively ran-
domized 612 patients with melanomas less than 2 mm
thick to receive excision with either 1-cm (narrow) or 3-cm
(wide) margins [12]. There were no local recurrences
among patients with melanomas thinner than 1 mm,
regardless of the excision margin.  Of interest was the
2.7% risk of local recurrence in patients with melanomas
1.1–2 mm thick with 1-cm resection margins, whereas no
local recurrences were seen in the same group of patients
who received 3-cm margins. There was no difference
between the two groups in the disease-free and overall
survival rates after a median follow-up of 55 months.
Updated data after 15 years again showed no difference in
overall survival and disease-free survival for the two
study arms [8]. The WHO Melanoma Group trial clearly
demonstrated that a narrow excision margin for thin (i.e.,
less than 1 mm) melanomas is safe and provides excellent
local control.
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Management of the regional lymph nodes
The regional lymph nodes are the most-common site of
metastases and the likelihood of finding metastatic disease
is highly dependent on the depth of the primary lesion. In
patients with no palpable nodal disease, primary lesions
less than 1 mm thick have a <10% likelihood of having
nodal metastases. This number increases to 20% for
lesions 1.01–2.00 mm thick, 33% for lesions 2.01–4.0 mm
thick, and 40% for lesions >4.0 mm thick [13]. 
Approximately 5% of patients present with clinically
apparent regional lymph node involvement at the time of
diagnosis [14]. Any palpable nodes that are enlarged (gen-
erally ≥1–1.5 cm in maximum diameter) or very hard or
fixed to adjacent structures must be considered suspicious
for metastatic involvement. Metastatic nodal involvement
can usually be verified with a fine needle aspiration biop-
sy. Patients with biopsy proven palpable nodal involve-
ment should undergo wide local excision of the primary
tumor and complete lymph node dissection (LND), as sur-
gical excision may be curative. For patients with gross
axillary disease, the axillary lymphadenectomy should
include levels I, II, and III nodes to provide the best
regional control. For patients with inguinal disease, the
extent of lymphadenectomy is more controversial, given
the high rate of complications involved with deep inguinal
LND. In one study, deep inguinal lymph nodes were
involved in 43% of patients with palpable inguinal nodes,
advocating complete superficial and deep inguinal LND in
these patients [15]. Others reserve deep inguinal node dis-
section for the patients with a positive Cloquet’s node or
multiple involved nodes.
Given the high incidence of metastasis to the regional
lymph nodes in patients without palpable disease, it is log-
ical to believe that prophylactic or elective lymphadenec-
tomy may be beneficial with clinically negative nodes.
Since Snow first recommended complete lymph node dis-
section in patients without nodal disease in 1892 [3], advo-
cates have claimed that resection of occult metastases in
the regional nodes could prevent disseminated disease and
therefore lead to improved disease-free survival as well as
overall survival. A retrospective review compared 10-year
survival statistics for patients with localized melanomas
(stage I and II) who underwent wide excision alone with
those who underwent wide excision plus elective lymph
node dissection (ELND) [16]. Patients with intermediate-
thickness melanomas (0.76–4 mm) who underwent wide
excision plus ELND had a significantly higher survival
rate than those who had wide excision alone, even after the
analysis was stratified for tumor sites.  In contrast, there
was no survival benefit for ELND in patients with either
thin (≤0.75 mm) or thick (≥4 mm) lesions. Similarly, a sec-
ond retrospective review in 1988 again suggested a sur-
vival advantage for ELND compared with clinical staging
with subsequent therapeutic dissection at the time of nodal
recurrence [17].   
Critics counter that an ELND exposes many node-neg-
ative patients to the morbidity of a LND. Any number of
unaccounted variables may have played a role in the choice
between ELND and therapeutic LND, thus calling the con-
clusions of the retrospective data into question [18]. In con-
trast to the data derived from retrospective reviews, a num-
ber of prospective studies addressing ELND have found no
survival benefit for patients treated with ELND [19, 20]. A
small study conducted by the Mayo Clinic found no dis-
ease-free or overall survival advantage for ELND [20]. The
WHO Melanoma Group randomized two groups of patients
to receive either wide excision plus ELND (n=267) or wide
excision with subsequent therapeutic lymphadenectomy if
clinically indicated (n=286) [19]. Analysis of these data
revealed no difference in survival between the two groups.
With follow-up now at greater than 20 years, the WHO
Trial 1 comparing wide local excision alone versus wide
local excision combined with ELND still shows no statisti-
cal improvement in either survival or disease-free interval
[8]. At 8 years of follow-up, the WHO Trial 14 which com-
pared excision only with excision plus ELND in patients
with melanoma of the trunk showed a borderline difference
in survival, benefiting patients undergoing ELND [8, 21]. 
The largest trial to examine the issue was the Intergroup
Melanoma Surgical Program, randomizing 740 stage I and
II melanoma patients to ELND or observation [22].
Overall, there was no significant difference between the
two groups. However, a significant improvement in sur-
vival with ELND was seen in certain subsets, including
patients younger than 60 years or patients with non-ulcer-
ated primaries. Long-term results confirmed no significant
10-year survival difference between ELND or observation
(77% vs. 73%, P=0.12) [23]. However, a significant reduc-
tion in mortality with ELND was seen for patients with
non-ulcerated melanomas, tumors between 1.0 and 2.0 mm,
and limb melanomas. While it is possible that ELND bene-
fits a subset of melanoma patients, it does not appear to
improve survival for the majority of patients with clinical-
ly negative nodes.
The management of clinically node-negative melanoma
patients changed considerably with the advent of the sen-
tinel lymph node biopsy (SLNB), a technique based on the
anatomical concept that lymphatic fluid from defined
regions of skin drains specifically to an initial node or
nodes (“sentinel nodes”) prior to disseminating to other
nodes in the same or nearby basins. Morton et al. [24]
described this anatomical concept and described a reliable
method for surgical identification and removal of the sen-
tinel node draining the site of a cutaneous melanoma. More
importantly, this same group showed that the pathological
status of the sentinel node accurately determined whether
melanoma cells have metastasized to that specific lymph
node basin [25]. Other institutions have recapitulated these
results, confirming that melanoma patients with pathologi-
cally negative sentinel nodes have detectable metastases in
non-sentinel nodes less than 5% of the time [26, 27].
Regional recurrence after sentinel node biopsy is infre-
quent [28, 29].
An important aspect of SLNB is the ability to perform a
more-detailed histological examination of the sentinel
lymph nodes. Identification of micrometastases in sentinel
nodes is enhanced by careful sectioning of the node (step-
sectioning) as well as the use of immunohistochemical
staining with anti-S-100, anti-MART-1, or HMB-45 (anti-
gp100) antibodies [30]. Even microscopic foci of
melanoma detected only by immunohistochemical staining
are clinically significant. With this increased sensitivity,
sentinel lymph node status is the most-important predictor
of survival for patients with melanoma. Patients with a neg-
ative sentinel node are over 6 times more likely to survive
than those with a positive sentinel lymph node, making the
predictive impact of sentinel node status much greater than
any other prognostic factor [31]. 
Given the demonstrated prognostic power of SLNB,
elucidating the indications for the use of SLNB becomes
central. Several clinical factors correlate with the likeli-
hood of lymph node involvement and thus influence the
decision regarding SLNB. Cascinelli et al. [32] reported
sentinel lymph node positivity rates of 16% in lesions
thicker than 1.0 mm. Among the 829 patients in a WHO
study, positivity rates of 2% (<1.0 mm), 7% (1.0–1.99
mm), 13% (2.0–2.99 mm), and 31% (≥3.0 mm) were
reported. In addition to tumor thickness, other factors such
as tumor ulceration, young age, and mitotic rate have been
shown to be associated with sentinel lymph node positivity
[31, 33, 34]. Based on these data, as well as additional cor-
roborating studies, the SLNB procedure should be routine-
ly considered for primary melanomas deeper than 1.0 mm
and selectively applied for tumors 1.0 mm or less, when
other worrisome features are present.  
SLNB plays a central role in staging the regional lymph
nodes and is the standard of care in many major melanoma
centers [32]. With the widespread use of SLNB, the range
of survival rates among various subgroups of pathological
stage III (node-positive) patients is enormous, because of
“upstaging” based on a direct examination of the sentinel
lymph nodes by histopathological examination [35].
Furthermore, melanoma patients who were clinically
staged compared with those whose nodal disease was
staged pathologically differ significantly in their survival
rates [36]. Currently, the compelling prognostic value of
knowing the nodal status makes SLNB indispensable for
accurate staging, and thus a key component of future stud-
ies examining adjuvant therapy.
Patients who have a positive sentinel lymph node
should undergo a completion LND [37]. This “selective”
approach to node dissection spares patients with negative
nodes the morbidity of the procedure, while offering
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improved regional control and whatever survival benefit
there may be from elective dissection to the node-positive
patient. Additional positive non-sentinel lymph nodes
(NSN) will be found in 7%–33% of patients with a positive
sentinel node [24, 27, 31, 38–42], but predicting which
patients will have residual disease in the NSN is not cur-
rently possible [40, 43]. Even patients with the most-favor-
able primary melanomas have a substantial risk of addi-
tional disease in the basin. While still unproven, it is possi-
ble that early complete node dissection may impact sur-
vival in patients with microscopic disease in the sentinel
node. Although not a direct analogy to the sentinel node
biopsy situation, when the survival of patients in the WHO
Program 14 Trial with microscopic disease at ELND was
compared with those who had regional recurrences during
observation, the survival was significantly improved in the
former group (48.2% vs. 26.6%, P=0.04) [21, 43]. The
Multicenter Selective Lymphadenectomy Trial I has recent-
ly completed accrual, and will hopefully define the thera-
peutic benefit of SLNB and selective LND [44].
The role of adjuvant radiation therapy to the nodal basin
after resection of regionally advanced melanoma has not
been clearly defined, although there is a growing body of
literature to support its use [45]. There is a high risk of
regional failure-up to 50%-after therapeutic cervical LND,
especially in the presence of large-sized nodes, multiple
involved nodes, or extracapsular extension [45]. Several
non-randomized studies have suggested that postoperative
radiation to the neck or axilla after radical LND decreases
regional recurrence rates in node-positive patients [45–48].
Only one small randomized trial of adjuvant radiotherapy
has been completed in cutaneous melanoma, and this yield-
ed a negative result [49]. This study utilized conventional
radiation fractions and a treatment break, both currently
felt to be suboptimal for melanoma. The Radiation Therapy
Oncology Group initiated a randomized trial of postopera-
tive radiation using larger treatment fractions in patients
undergoing neck dissections for melanoma.  Accrual to this
trial was poor, however, and the trial ultimately failed to
meet its accrual goal [50]. Another randomized trial is
presently underway in Australia. Until larger randomized
trials are conducted, it is reasonable to consider postopera-
tive radiation therapy in patients with gross extracapsular
extension or multiple involved lymph nodes.  
Adjuvant therapy for high-risk melanoma
The poor prognosis once melanoma has metastasized has
generated significant interest in reducing recurrence rates
through adjuvant therapies. Many of these trials were per-
formed prior to a full understanding of recognized prog-
nostic factors, and hence risked potential imbalances
between the treatment and control arms. Compounding
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these problems were small sample sizes and the inclusion
of heterogeneous groups of at-risk patients in many of the
adjuvant trials conducted to date. It is important to bear in
mind that these methodological problems make compar-
isons of trials difficult, even when the trials are purporting
to study similar interventions, and they preclude lending
serious weight to the results of subset analyses. A large
variety of different interventions have been tested in the
randomized trials conducted to date.
Retinoids and hormones
The use of oral vitamin A for the adjuvant therapy of
melanoma in humans was examined in a randomized, con-
trolled trial conducted by the Southwest Oncology Group
(SWOG) beginning in 1981, based on preclinical studies in
the 1970s demonstrating the efficacy of retinoids against
melanoma both in vitro and in vivo. SWOG 8049 investi-
gated the use of oral vitamin A in 240 eligible melanoma
patients with tumors ≥0.75 mm in depth and clinically neg-
ative lymph nodes, and found no disease-free or overall
survival benefit [51]. Megestrol acetate (Megace), a prog-
esterone analogue, has also been studied, based on evi-
dence that the hormonal milieu may play a role in the clin-
ical course of melanoma. A small randomized clinical trial
of 67 eligible patients showed a survival benefit for mege-
strol [52]. This study prompted the performance of a larger
randomized, double-blind, placebo-controlled phase III
trial of megestrol in the treatment of high-risk melanoma in
the adjuvant setting. In this study of 262 eligible patients,
no relapse-free or overall survival benefit was seen in
patients receiving megestrol versus placebo [53].
Cytotoxic chemotherapy
Despite multiple trials involving a variety of cytotoxic
drugs available to clinical investigators throughout the
years, no confirmed studies have demonstrated a benefit of
adjuvant chemotherapy in melanoma patients at high risk
for relapse. Single agents with recognized but minimal
activity against advanced disease include dacarbazine
(DTIC), the nitrosoureas, the vinca alkaloids, cisplatin,
paclitaxel, and bleomycin. Although DTIC results in objec-
tive responses in up to 18%–22% of patients with metasta-
tic disease, numerous studies have failed to show a benefit
as postsurgical adjuvant [8, 54–56]. Multiagent cytotoxic
therapy has similarly been unfruitful in the adjuvant setting.
Karakousis and Emrich [57] found no benefit for the com-
bination of DTIC and estramustine in a small, three-arm
study comparing multiagent chemotherapy or BCG with a
no-treatment control group. Four two-arm, randomized
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controlled trials of multiagent chemotherapy have been per-
formed. A trial using BCNU, dactinomycin, and vincristine
[58] and a small trial of DTIC, CCNU, and vincristine [59]
both suggested a benefit for multiagent chemotherapy,
while two other trials did not [60, 61]. Several small trials
have also explored postoperative adjuvant therapy with
DTIC plus BCG, with [55, 62] or without a no-treatment
arm [63–67]. DTIC plus BCG does not appear to have any
efficacy in the adjuvant setting, which is hardly surprising
in view of the lack of activity of the individual agents and
the absence of any suggestion of synergy between them.
Tamoxifen and cisplatin has been shown to exhibit cytotox-
ic synergy in vitro. An initial phase II trial treating 153
patients with four cycles of tamoxifen and cisplatin for 28
days revealed a disease-free survival of 68.4% and an over-
all survival of 84.5% at 36 months follow-up.  The authors
argue that the projected 5-year disease-free survival and
overall survival were comparable to the results with inter-
feron in the ECOG 1684 trial, and therefore warranted fur-
ther investigation of cisplatin and tamoxifen [68]. A second
phase II study utilizing higher doses of tamoxifen and
weekly cisplatin, however, demonstrated only modest
activity (32% overall response rate) with only 1 patient
achieving a complete remission that lasted 22 months.
Furthermore, while the combination of tamoxifen and cis-
platin demonstrated some activity, the toxicity was substan-
tial and the authors did not recommend its clinical use at the
higher dosages used [69]. Until and unless randomized tri-
als in advanced disease confirm the efficacy of cytotoxic
chemotherapy, adjuvant systemic therapy should be consid-
ered only in the context of a clinical trial.  
Immunostimulants
Bacillus Calmette-Guerin (BCG) is a mycobacterial agent
that was shown by Morton in 1970 to elicit an antitumor
response when injected into cutaneous metastatic melanoma
nodules [70]. Interestingly, regression of non-injected tumor
nodules was also noted in some patients receiving this treat-
ment, suggesting that this effect was immune mediated [70,
71]. Based on these results, several randomized studies of
BCG therapy versus observation were conducted in patients
with resected primary melanoma greater than 1.5 mm in
thickness. None demonstrated a significant survival advan-
tage to BCG therapy in this setting [72]. The only study to
demonstrate a disease-free survival advantage of BCG ther-
apy over observation was a small trial of 20 eligible patients
with stage III disease [73].
BCG monotherapy was also compared with DTIC and
the combination DTIC and BCG [64]. Combination therapy
was found to be better than either modality alone, but BCG
therapy was not found to have efficacy greater than DTIC
alone. As there was no observation or placebo arm in this
trial, conclusions as to the efficacy of BCG alone could not
be drawn. Considering all of the data obtained from these
small trials together, there is no suggestion that BCG thera-
py provides any meaningful benefit in the adjuvant setting.
Heat-killed Corynebacterium parvum is another bacterial
agent that is thought to be immunostimulatory. Along the
same lines as BCG, the efficacy of C. parvum against high
risk melanoma in the adjuvant setting has been tested in sev-
eral clinical trials. Studies of C. parvum versus observation
[74] and placebo [75] have failed to demonstrate any bene-
fit. When compared with BCG therapy, however, two stud-
ies, [76, 77] have shown C. parvum therapy to confer a sta-
tistically significant survival advantage, although these stud-
ies did not have a placebo arm. Although a benefit of BCG
and C. parvum single-agent therapy over and above observa-
tion alone has not been definitively demonstrated, BCG con-
tinues to play a significant role as a control arm, as well as
an immune adjuvant in combination with vaccine therapy in
ongoing clinical trials.
Levamisole is an antihelminthic drug that has been
found to have immunostimulatory properties. While the
mechanism of immunopotentiation of this agent is not well
understood, it has nevertheless been investigated as an anti-
cancer agent.
Of the four randomized, controlled studies of lev-
amisole in the treatment of high-risk melanoma [55,
78–80], three failed to show a statistically significant ben-
efit from levamisole therapy as far as disease-free or over-
all survival. The fourth study, by Quirt et al. [78], did
demonstrate a trend towards a disease-free and overall sur-
vival benefit of levamisole, although it was of borderline
statistical significance. Levamisole has also been tested in
combination with interleukin-2 in two randomized studies
of patients with advanced melanoma, but no benefit was
obtained [81, 82]. No further investigations are planned for
this agent.
Transfer factor is an extract obtained from disrupted
leukocytes that was first described by Lawrence in 1955
[83]. When prepared from leukocytes from an antigen-sen-
sitized donor and then administered to a naïve recipient,
transfer factor has been shown to elicit delayed-type hyper-
sensitivity responses. Early applications of transfer factor
therapy were based on the hypothesis that its mechanism of
action was antigen specific. To this end, transfer factor used
in preliminary investigations of its role in the treatment of
melanoma was obtained from donors whose lymphocytes
demonstrated reactivity to melanoma antigens (typically
melanoma patients who had undergone disease regression
or surgical cure, and family members and close contacts of
the study subjects) [84, 85]. Based on encouraging results
obtained in these early studies in patients with metastatic
disease [84, 85], two small clinical trials were performed to
test the efficacy of transfer factor on melanoma in the adju-
vant setting [86, 87]. The material used for these studies
was obtained from normal healthy donors, based on the
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knowledge that transfer factor exerts both specific and non-
specific effects on cellular immunity. Neither of these trials
demonstrated a disease-free or overall survival benefit due
to transfer factor therapy. There is currently no role for
transfer factor in the adjuvant therapy of melanoma.
Granulocyte macrophage colony stimulating factor
Cytokines with roles in the growth and maturation of
hematopoietic and dendritic cells, such as granulocyte/
macrophage colony stimulating factor (GM-CSF), have been
incompletely studied in the adjuvant setting. No prospective,
randomized, multicenter trials have yet been completed with
these agents to support their use in the adjuvant therapy of
high-risk melanoma outside clinical investigations.  In one
phase II trial investigating GM-CSF as surgical adjuvant ther-
apy in patients with stage III or IV melanoma, Spitler et al.
[88] showed that GM-CSF prolonged overall and disease-free
survival compared with matched historical controls. This has
prompted a number of prospective intergroup trials that are
currently investigating the potential function of GM-CSF. One
such trial is the ECOG trial E4697, which is evaluating GM-
CSF (alone or administered with vaccination against a multi-
epitope peptide vaccine) among patients with resectable dis-
ease, advanced regional nodal disease with extracapsular
extension, or failure after adjuvant interferon therapy [89].
Definitive recommendations regarding the use of GM-CSF in
the adjuvant setting for melanoma must await the results of
these trials.      
High dose interferon-α2b
In 1980, interferon (INF) was shown to inhibit the growth
of B16 melanoma in vitro and in vivo [90]. Since then,
multiple trials involving adjuvant IFN-α have involved a
wide range of dosing regimens [91]. Early trials utilized
low-or intermediate-dose regimens, and while there was a
suggestion of some effectiveness [92, 93], re-analysis and
additional trials have demonstrated no benefit to survival
[94, 95]. Although there was no overall survival advantage,
the disease-free survival advantage to low-dose IFN seen in
the French and Austrian trials has led to its approval in
Europe for thick primary melanomas [66, 67]
Unfortunately, the recently published results of the AIM-
HIGH study in the United Kingdom of low-dose extended-
duration IFN-α2a demonstrated no clear differences
between IFN and observation in either overall or relapse-
free survival for any subset of patients [98]. 
Kirkwood et al. [99] dramatically increased the dose of
INF to the maximally tolerated dose in a randomized trial
for ECOG, E1684. This regimen involved an “induction”
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phase of IFNα-2b 20 MU/m2 IV 5 days a week for 4 weeks,
followed by a “maintenance” phase of 10MU/m2 Sq 3 days
a week for the remainder of a year. While this regimen was
more toxic, the results were positive. Patients randomized
to the treatment group had a significant improvement in
disease-free and overall survival compared with the control
group. IFN-α2b therapy increased the median relapse-free
survival by 9 months (1.72 years for IFN-α2b patients ver-
sus 0.98 years for observation patients) and produced a
42% improvement in the 5-year relapse-free survival rate
[46% for IFN-α2b patients (95% confidence interval
19%–34%) versus 37% for observation patients (95% con-
fidence interval 30% to 46%)]. Based on these results, IFN-
α2b was approved by the`FDA foz the adjuvant treatment
of high-risk melanoma.  
In order to verify the results of E1684, as well as better
define the benefit of adjuvant therapy with melanoma, an
ECOG-coordinated Intergroup trial was initiated as a fol-
low-up to E1684. E1690 compared the high-dose IFN-α2b
and a 2-year low-dose IFN-α2b with to observation after
complete resection of all known disease [100]. While the
results of this trial confirmed the disease-free survival
advantage for high-dose IFN-α seen in E1684, there was no
overall survival advantage.
A third trial, Intergroup E1694, compared 1 year of
high-dose IFN-α2b with 2 years of a ganglioside vaccine
called GMK. Gangliosides are carbohydrate antigens found
on the surface of melanoma cells, as well as normal cells of
neural crest origin and tumor cells of other types. A ran-
domized trial suggested a disease-free survival benefit in
patients who were treated with GM2 plus BCG compared
with those treated with BCG alone following resection of
stage III disease [101]. In May 2000, the E1694 Trial’s
Independent Data Safety Monitoring Committee concluded
that the high-dose IFN arm was associated with signifi-
cantly improved relapse-free and overall survival, and
mandated that the study be terminated early and the results
disclosed [102]. 
Advocates of IFN point out that of the three high-dose
trials described above, all three demonstrated improve-
ment in relapse-free survival, and two of the three demon-
strated an improvement in overall survival. In addition,
advocates of adjuvant IFN therapy point out that the rea-
son that E1690 failed to demonstrate a survival advantage
is likely due to differences in eligibility criteria and, more
importantly, the subsequent availability of post-relapse
IFN-α2b crossover therapy in the E1690 trial compared
with E1684 [100].   
However, several questions still remain as to whether
these trials support a role for IFN in the adjuvant setting.
Despite the enthusiasm and multiple large controlled stud-
ies, there has been no demonstrable rationale of the mech-
anisms of action of this biological response modifier [8].
ECOG 1684, the trial that established the adjuvant use of
IFN-α2b is not without concerns. Patients were not strati-
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fied by the number of positive lymph nodes; a recognized
prognostic factor. Therefore it is possible that there may
have been an unrecognized imbalance between the treat-
ment and control groups that influenced the outcome. In
addition, longer follow-up data on ECOG 1684 show that
at a median follow-up of 12.6 years there is a continued
disease-free survival advantage for high-dose IFN, but the
benefit in overall survival loses statistical significance
[103]. A pooled analysis of updated data from E1684 and
E1690 demonstrates that relapse-free survival, but not
overall survival, was significantly prolonged for patients
treated with high-dose IFN versus observation [103].
Therefore, while high-dose IFN clearly improves disease-
free survival, the question of overall survival remains con-
troversial [91]. 
The concerns about E1684, specifically the possible
imbalance between the treatment and control groups, were
supposed to be addressed in E1690. However, while there
was an improvement in disease-free survival for high-dose
IFN-α2b, the study failed to demonstrate an improvement
in overall survival for either high- or low-dose IFN-α2b.
The crossover data from 1690, which advocates of IFN
therapy use as the reason E1690 failed to validate E1684,
are from a retrospective analysis and must be considered
unproven. Finally, E1694 appears to confirm the disease-
free and overall survival benefit of high-dose IFN-α2b
demonstrated in ECOG 1684. However, this study did not
have an observation arm. Therefore, a deleterious effect of
the GMK vaccine cannot be ruled out. While this appears
unlikely, such an effect would lead to the appearance of a
“benefit” for IFN-α2b in that trial when none existed.
With so many differences between the trials, it is difficult
to directly compare the results.
Given the significant side effects of high dose IFN,
there is considerable interest in realizing the potential ben-
efit of interferon without the toxicities associated with the
regimen. ECOG 1697 is currently examining whether
patients with stage II or stage III (one lymph node positive
only) melanoma benefit from just the induction phase of
high-dose IFN-α2b. EORTC study 18991 is investigating
the use of low-dose pegylated IFN-α2b over 5 years in
high-risk patients. EORTC 18-952 has enrolled more than
1,400 node-positive patients in a three-armed study of
adjuvant intermediate dose IFN-α2b. In this study, the effi-
cacy of two intermediate-dosing regimens of IFN-α2b, 10
MU SC 3 times a week for 4 weeks, followed by either 10
MU SC 3 times a week for 1 year, or 5 MU SC 3 times a
week for 2 years are compared with observation. The
Scandinavian Melanoma Cooperative Group is randomiz-
ing patients between observation or one of two intermedi-
ate dose regimens (10 MU SC 5 times a week for 1 month
followed by 10 MU SC 3 times a week for 1 or 2 years).
Until the results of these studies show that an intermediate
dose of IFN is as effective, high-dose IFN-α2b remains the
standard therapy in the adjuvant setting.
In-transit metastasis
Approximately 2%–3% of melanoma patients will develop
in-transit metastasis, which is the appearance of metastasis
along the path from the primary tumor to its regional nodal
basin, and which is lymphatic in nature. The management
of local or in-transit metastasis is dictated by the number
and the size of the lesions. With isolated local recurrence
that is few in number, surgical excision is the best option.
Surgery consists of excision of metastases with a margin of
surrounding normal cutaneous and subcutaneous tissue.
When there are multiple local recurrences, excision
becomes an unlikely option and the more reasonable
options include intralesional therapy, hyperthermic isolated
limb perfusion (ILP), and radiation therapy.
Intralesional therapy is desirable in that it does not have
the systemic toxicity as many other therapeutic modalities.
Local injection of multiple agents such of fotemusine [104],
bleomycin [105], cisplatin [106], IL-2 [107], and IFN-α
[108], has been investigated as a method of controlling cuta-
neous and subcutaneous metastatic melanoma.  Another com-
monly used intralesional therapy GM-CSF, which can result
in significant regression of melanoma deposits [109, 110].
Although melanoma is relatively radiation resistant, it can
provide palliation in unresectable lesions in approximately
two-thirds of cases [45, 111]. The response of dermal, subcu-
taneous, or lymph node metastases to the radiation therapy
depends mainly on their size. Complete response was seen in
71% of patients with lesions less than 3 cm, but only in 20%
in patients with lesions >5 cm in size [112]. Therefore, radia-
tion therapy should be considered in those patients with
smaller volume of cutaneous or subcutaneous metastases.     
Hyperthermic isolated limb perfusion is a way of isolat-
ing the blood circuit to the extremity and administering
chemotherapeutic agents regionally at a concentration 15–25
times higher without resulting in systemic side effects [113].
Melphalan has been used as a standard drug for ILP sec-
ondary to its efficacy and low regional toxicity [114, 115].
While this has not been shown to improve survival, the use
of hyperthermic provides a significant palliation of locore-
gional symptoms when other options are not available.
Isolated limb infusion (ILI) is a technically less-complex
variation of ILP, in which a low-flow perfusion is performed
via percutaneously inserted catheters, but without oxygena-
tion [116]. The early results seem to be similar to those
obtained by ILP, although further evaluation is needed before
definitive recommendation can be made [117]. 
On the horizon – vaccine therapy
Based on evidence that the immune system plays a natural
role in melanoma progression, there has been hope that the
power of the immune system could be harnessed through
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the use of melanoma vaccines. While multiple trials have
demonstrated the ability to generate an anti-tumor immune
response, to date no large, randomized trial has demon-
strated an impact on survival with any melanoma vaccine.
As opposed to other adjuvant therapies where we accept
small gains in exchange for significant toxicity, the side
effects of vaccines are limited, confined mostly to mild flu-
like symptoms and reactions at the injection site.
Therefore, there remains considerable interested in devel-
oping improved vaccine strategies that will make a signifi-
cant clinical impact. 
One common approach has been to vaccinate patients
with antigens present on melanoma cells. Bystryn et al.
[118] used antigens shed into culture from three human and
one hamster melanoma cell lines to create a polyvalent
melanoma antigen vaccine capable of generating both a
humoral and cellular response in a subset of patients.
Recently, this vaccine was evaluated in a randomized phase
II study involving a high-risk stage III patient population,
and demonstrated a statistically significant disease-free
survival advantage for the vaccine arm [119]. A statistical-
ly non-significant overall survival advantage was seen in
the vaccine arm. Gangliosides have also been found to be
effective targets for active immunotherapy [119–122].
Gangliosides are glycosphingolipids present on melanoma
cells, as well as some non-neoplastic cells, with carbohy-
drate moieties expressed on the cell surface available for
antibody recognition [123]. Vaccinating patients with the
GM2 ganglioside along with the adjuvant BCG had
promising results [101], which were improved by conju-
gating GM2 to keyhole limpet hemocyanin (KLH) and
replacing the BCG with the adjuvant QS-21 [124, 125]. In
a randomized trial, this vaccine was shown to be less effec-
tive than high-dose IFN in patients with resected stage IIB-
III melanoma [102]. It is currently being studied in a
European (EORTC) trial in stage II melanoma patients
comparing the same vaccine with observation after surgery. 
Rather than using single or multiple antigens, several
researchers have attempted to use entire cells to stimulate
an immune response. Autologous cellular vaccines require
the surgical resection of the melanoma, which, after being
irradiated or lyzed, are given back to the patient along with
an adjuvant to promote immune recognition. Berd et al.
[126] tested a novel vaccine in which the hapten ditnitro-
phenyl was conjugated to proteins on autologous tumor
cells in order to increase the immunogenicity. In a total 77
patients with clinically evident nodal metastases were
given the vaccine with BCG, now called “M-Vax,” in the
adjuvant setting after lymphadenectomy. The authors
reported a more favorable than expected 5-year relapse-
free and overall survival rate (45% and 58%, respectively)
[127, 128]. A multi center randomized controlled trial of
M-Vax as adjuvant therapy for resected AJCC stage III
melanoma had significant difficulty with specimen trans-
portation, illustrating the difficulties of performing large
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trials with autologous vaccines. The use of autologous
tumor cell vaccines is limited to individuals with palpable
nodal disease or resectable metastatic disease so that suffi-
cient tumor can be obtained to prepare a vaccine, and even
then there is only enough tumor to provide a limited num-
ber of vaccinations. In addition, such patients have a poor
overall prognosis and are likely to have significant residual
tumor burden, making them less-than-ideal candidates for
any immunotherapeutic approach.  
Allogeneic cellular vaccines take advantage of the fact
that melanoma-associated antigens are shared among a
large number of patients.  There is well-documented evi-
dence that this type of vaccination can induce immune
responses to several melanoma antigens [129, 130].
Allogeneic vaccines are readily available, even for patients
who lack sufficient tumor to produce an autologous tumor
cell vaccine, and can be standardized, preserved and dis-
tributed in a manner akin to any other therapeutic agent.
Because of this, they are more readily available for evalua-
tion in large prospective, randomized trials.  Presently,
there are two major allogeneic vaccines being evaluated as
an adjuvant therapy for melanoma. 
Canvaxin is an allogeneic vaccine composed of three
viable irradiated melanoma cell lines, chosen for their high
content of immunogenic melanoma- and tumor-associated
antigens [131, 132]. This vaccine has been shown to
enhance the immune response to melanoma, and this
response correlates with outcome [129, 133–137]. In a
phase II trial, 935 patients with AJCC stage III melanoma
who underwent complete lymphadenectomy were treated
with the vaccine. Compared with a historical cohort of
1,677 similar patients who did not receive the vaccine,
median overall survival and 5-year overal survival were
significantly higher [138]. Currently a multicenter, ran-
domized, controlled trial is underway comparing Canvaxin
plus BCG with placebo plus BCG in both stage III and
stage IV melanoma status post surgical resection.
Melacine consists of a lysate of two homogenized
melanoma cell lines that are combined with the adjuvant
DETOX (“detoxified Freund’s adjuvant,” composed of
monophosphoryl lipid A and a purified mycobacterial cell-
wall skeleton) [139, 140]. In stage IV melanoma, vaccina-
tion with Melacine induced an objective response in 19%
of patients [141], and resulted in a median survival compa-
rable to combination chemotherapy (dacarbazine, cisplatin,
BCNU, and tamoxifen) with significantly less toxicity
[142, 143]. Based on these results, Melacine was approved
in Canada in May 2000 for the treatment of advanced
melanoma.
The Southwest Oncology Group (SWOG) completed a
randomized trial comparing adjuvant Melacine with obser-
vation for patients with intermediate thickness (1.5–4.0
mm), node-negative melanoma [144]. Although there was
no significant advantage of the vaccine compared with
observation, it had previously been reported that melanoma
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patients who expressed at least two of the following five
alleles: HLA-A2, A28, B44, B45, and C3, had a significant
response when given the vaccine [142]. Patients in the
SWOG trial in the vaccine arm who expressed two or more
of these alleles had a superior disease-free survival than the
corresponding patients in the observation arm (4-year dis-
ease-free survival 87% vs. 64%, P=0.0001). The specific
alleles contributing the major component of this effect
were HLA-A2 and C3. A2+ and/or C3+ vaccinated patients
[178 patients of 294 total vaccine arm patients (61%)] had
an 82% 4-year disease-free survival (P=0.001 compared
with observation arm or A2/C3- vaccine arm patients)
[145]. A follow-up trial of adjuvant Melacine limited to
patients with HLA A2 or C3 is presently being planned.
Conclusions
Early detection, and ultimately prevention, of melanoma
remains the best way to minimize morbidity and mortality
from this increasingly common form of cancer.  Aggressive
surgical approaches can salvage some patients with even
advanced disease, while the use of sentinel node biopsy has
allowed the identification and early surgical treatment of
patients with occult nodal metastases.  Adjuvant therapy is
a logical way to impact the natural history of high-risk
melanoma; to date only high-dose IFN has been shown in
clinical trials to improve relapse-free survival and possibly
overall survival. New approaches continue to be needed to
treat metastatic melanoma and to prevent metastases from
occurring.
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